BiondVax Pharmaceuticals Ltd. | CIK:0001611747 | 3

  • Filed: 4/30/2018
  • Entity registrant name: BiondVax Pharmaceuticals Ltd. (CIK: 0001611747)
  • Generator: Ez-XBRL
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1611747/000121390018005179/0001213900-18-005179-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1611747/000121390018005179/bvxv-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001611747
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory

    NOTE 16:- SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF COMPREHENSIVE INCOME

     

    a. Research and development expenses, net of participations:

     

                           

    Convenience translation

    (Note 2c)

    		  
         

    Year ended December 31,

    		    

    Year ended

    December 31,

    		  
          2015     2016     2017     2017  
          N I S     U.S. dollars  
                                       
      Salaries and related expenses     3,796       3,808       3,695     $ 1,066  
      Share-based payment     588       903       388       112  
      Patent registration fees     617       358       322       92  
      Rentals and maintenance of laboratory     607       610       610       153  
      Materials and subcontractors     4,633       3,145       3,797       1,118  
      Revaluation of the liability with respect to the IIA grants     -       -       10,300       2,971  
      Depreciation     495       573       311       90  
                                       
            10,736       9,397       19,423       5,602  
                                       
      Participation by IIA and UNISEC     (2,830 )     (1,603 )     (646 )     (186 )
                                       
            7,906       7,794       18,777     $ 5,416  

     

    b.

    Marketing, general and administrative expenses:

     

                           

    Convenience translation

    (Note 2c)

    		  
         

    Year ended December 31,

    		    

    Year ended

    December 31,

    		  
          2015     2016     2017     2017  
          N I S     U.S. dollars  
                                       
      Salaries and related expenses     519       587       622     $ 179  
      Share-based payment     157       358       131       38  
      Professional services     1,952       2,595       3,338       963  
      Rentals, office expenses and maintenance     212       201       203       59  
      Depreciation     133       48       130       37  
      Other     424       317       455       131  
                                       
            3,397       4,106       4,879     $ 1,407  

     

    c. Financial income and expense:

     

                           

    Convenience translation

    (Note 2c)

    		  
         

    Year ended December 31,

    		    

    Year ended

    December 31,

    		  
          2015     2016     2017     2017  
          N I S     U.S. dollars  
             
      Financial income:                                
      Interest income on deposits     11       55       18     $ 5  
      Exchange differences, net     553       -       -       -  
      Revaluation of warrants     554       2,951       -          
      Revaluation of marketable securities     10       13       -          
                                       
            1,128       3,019       18       5  
      Financial expenses:                                
      Exchange differences, net     -       276       2,871       828  
      Revaluation of warrants                     7,969       2,299 
      Bank commissions and other financial expenses     24       27       73       21  
                                       
            24       303       10,913     $ 3,148